Search
for
Sort by
Research 61–90 of 69
- New and Emerging Therapies for Alopecia Areata
- Poster Presentations
- Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID‐19 pandemic: Insights from Google Trends
- Safety of Platelet‐Rich Plasma Subepithelial Infusion for Vocal Fold Scar, Sulcus, and Atrophy
- Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
- Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study
- Pharmacotherapy for Keloids and Hypertrophic Scars
- Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- Drug-induced alopecia after dupilumab therapy
- Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report
- Dupilumab‐associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study
- Learning From Success and Failure: Biologics for Non-approved Skin Diseases
- Dupilumab‐induced psoriasis in a patient with atopic dermatitis and alopecia totalis: A case report and literature review
- Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis
- Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis
- Dupliumab therapy for alopecia areata: a case series and review of the literature
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
- Alopecia areata-like and psoriasis after dupilumab use for atopic dermatitis
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis
- Dupilumab Alters Both the Bacterial and Fungal Skin Microbiomes of Patients with Atopic Dermatitis
- Dupilumab for the treatment of alopecia areata in children with atopic dermatitis
- Dupilumab in a 9-week-old with Netherton Syndrome Leads to Deep Symptom Control
- Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: A scoping review
- Friend or foe: A systematic review of dupilumab and alopecia areata
- Biologics in the management of childhood atopic dermatitis
- A Potential Role for IL-4 and IL-13 in an Alopecia Areata–Like Phenotype: A Clinical Perspective
- Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report